Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wim P J Witjes

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
European Urology|June 16, 2016
Re: DNA-repair Defects and Olaparib in Metastatic Prostate CancerWim P J Witjes
European Urology|April 15, 2014
Reply from authors re: Bertrand Tombal. Zometa European Study (ZEUS): another failed crusade for the holy grail of prostate cancer bone metastases prevention? Eur Urol 2015;67:492-4: ZEUS: the quest for the holy grail of prostate cancer bone metastases prevention continuesWim P J Witjes, Anup Patel, Manfred Wirth
European Urology|July 23, 2020
Reply to Emre Karabay and İlker Tınay's Letter to the Editor re: Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066Marc-Oliver Grimm, Christien Caris, Wim P J Witjes, et al.
Urologia Internationalis|June 16, 2012
Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonatesAxel Heidenreich, Wim P J Witjes, Truls E Bjerklund-Johansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trialRianne J M Lammers, Wim P J Witjes, Maria H D Janzing-Pastors, et al.
World Journal of Urology|May 31, 2015
Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validationRianne J M Lammers, Jan C M Hendriks, O Rodriguez Faba Rodriguez Faba, et al.
BJU International|December 6, 2013
Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapyRianne J M Lammers, Joan Palou, Wim P J Witjes, et al.
European Urology|July 29, 2011
Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancerRianne J M Lammers, Wim P J Witjes, Kees Hendricksen, et al.
Urology|March 7, 2002
A method for estimating within-patient variability in maximal urinary flow rate adjusted for voided volumeGabe S Sonke, Chris Robertson, André L M Verbeek, et al.
European Urology|November 26, 2013
Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trialMarc Colombel, Axel Heidenreich, Luis Martínez-Piñeiro, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
European Urology|June 16, 2016
Re: DNA-repair Defects and Olaparib in Metastatic Prostate CancerWim P J Witjes
European Urology|April 15, 2014
Reply from authors re: Bertrand Tombal. Zometa European Study (ZEUS): another failed crusade for the holy grail of prostate cancer bone metastases prevention? Eur Urol 2015;67:492-4: ZEUS: the quest for the holy grail of prostate cancer bone metastases prevention continuesWim P J Witjes, Anup Patel, Manfred Wirth
European Urology|July 23, 2020
Reply to Emre Karabay and İlker Tınay's Letter to the Editor re: Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066Marc-Oliver Grimm, Christien Caris, Wim P J Witjes, et al.
Urologia Internationalis|June 16, 2012
Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonatesAxel Heidenreich, Wim P J Witjes, Truls E Bjerklund-Johansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trialRianne J M Lammers, Wim P J Witjes, Maria H D Janzing-Pastors, et al.
World Journal of Urology|May 31, 2015
Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validationRianne J M Lammers, Jan C M Hendriks, O Rodriguez Faba Rodriguez Faba, et al.
BJU International|December 6, 2013
Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapyRianne J M Lammers, Joan Palou, Wim P J Witjes, et al.
European Urology|July 29, 2011
Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancerRianne J M Lammers, Wim P J Witjes, Kees Hendricksen, et al.
Urology|March 7, 2002
A method for estimating within-patient variability in maximal urinary flow rate adjusted for voided volumeGabe S Sonke, Chris Robertson, André L M Verbeek, et al.
European Urology|November 26, 2013
Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trialMarc Colombel, Axel Heidenreich, Luis Martínez-Piñeiro, et al.
Pageof 2